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comprehensive assessment of inference 
algorithms. As the authors point out, infor-
mation-theoretic approaches are not ideal 
for reconstructing small-scale networks, 
but seem to do quite well for reconstruct-
ing large-scale networks. An obvious 
development along these lines would be 
to increase the size and complexity of the 
gold-standard synthetic gene network by 
including additional genes and interac-
tions. Ideally, it would be useful to have a 
library of diverse, gold-standard synthetic 
gene networks, including ones consist-
ing of 25–100 genes and varied network 
architectures. As DNA synthesis capa-
bilities become less error prone and more 
cost effective, creating such a library will 
become feasible.
It would also be useful to expand the 
gold-standard synthetic networks to 
include additional components, such as 
small RNAs and microRNAs, and to take 
account of pre- and posttranscriptional 
and translational modifications. These 
developments would enable one to con-
sider multiple levels of regulation and to 
integrate different types of data in net-
work inference studies. These enhanced 
capabilities could lead to the develop-
ment of new systems biology techniques 
and analysis tools.
The work by Cantone and colleagues 
nicely illustrates the value of integrat-
ing the bottom-up network construction 
approaches of synthetic biology with the 
top-down network inference methodolo-
gies of systems biology. These efforts 
will be applicable to many different 
organisms, and may one day enable us 
to reverse engineer the gene regulatory 
networks that make up an elephant.
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Mutations in the gene encoding the orphan nuclear receptor Nurr1 are linked to a rare familial 
form of Parkinson’s disease. By examining the function of its mouse homolog, Saijo et al. (2009) 
provide evidence that Nurr1 protects dopaminergic neurons by suppressing inflammatory gene 
expression in astrocytes and microglia.26 Cell 137, April 3, 2009 ©2009 Elsevier Inc.neurotoxic challenge than those of wild-
type mice (Le et al., 1999). In this issue, 
Saijo et al. (2009) present evidence for an 
unexpected mechanism by which Nurr1 
mediates neuroprotection. These authors 
show that mouse Nurr1 acts in microglia 
and astrocytes to suppress the produc-
tion of inflammatory mediators that trig-
ger the death of dopaminergic neurons.
The NR4A subfamily of nuclear recep-
tors consists of three members: NR4A1, 
NR4A2, and NR4A3 (also known as Nur77, ate its neuroprotective effects primarily 
through its function in neurons. Nurr1 was 
initially characterized in rats as a tran-
scription factor that regulates expression 
of the gene encoding tyrosine hydroxy-
lase, a key enzyme in dopamine synthesis 
(Sakurada et al., 1999). Genetic deletion 
of Nurr1 in mice inhibits the develop-
ment of midbrain dopamine-producing 
neurons (Zetterstrom et al., 1997), and 
the dopaminergic neurons of heterozy-
gous null mice are more susceptible to Parkinson’s disease is a neurodegenera-
tive disorder, characterized by tremors 
and rigidity, that results from the progres-
sive loss of dopamine-producing neurons 
in the substantia nigra of the brain. Among 
the genetic factors contributing to the 
disease are rare mutations in the orphan 
nuclear receptor Nurr1 (also known as 
NR4A2) that are associated with a familial 
late-onset form of the disease (Le et al., 
2003). Prior work on Nurr1 is consistent 
with the view that this protein might medi-
Nurr1, and Nor1) (Maxwell and Muscat, 
2006). Unlike many other nuclear recep-
tors, the NR4As do not possess ligand-
binding cavities. Instead, NR4As are 
immediate early genes whose expression 
is induced by various stimuli including 
cyclic AMP, growth factors, inflamma-
tory signals, and hormones. The activity 
of NR4A is thought to be controlled pri-
marily at the level of protein expression 
and posttranscriptional regulation. NR4A 
receptors positively regulate the expres-
sion of target genes by directly binding 
to response elements in their promoters 
(Maxwell and Muscat, 2006).
In addition to positively regulating gene 
expression, nuclear receptors can also 
inhibit transcription. Recent work from 
several groups has begun to elucidate 
the transcriptional mechanisms through 
which nuclear receptors repress inflam-
matory gene expression. For example, 
the ligand-activated nuclear receptors 
PPAR and LXR inhibit inflammation 
through protein-protein interactions with 
the inflammatory transcription factor 
NF-κB (Bensinger and Tontonoz, 2008). 
Importantly, this so-called “transre-
pression” mechanism does not depend 
on direct binding of the receptors to 
response elements in target promoters. 
Instead, ligation of PPAR and LXR inhib-
its inflammatory gene expression by pre-
venting the inflammatory signal-specific 
removal of the corepressor complexes 
containing SMRT and NCoR from inflam-
matory gene promoters (Ghisletti et al., 
2007; Pascual et al., 2005).
Saijo et al. now reveal a previously 
unappreciated function for Nurr1—
the repression of inflammatory gene 
expression. This repression provides 
protection from the damaging effects 
of neuroinflammation and suggests 
new potential mechanisms linking Nurr1 
function and Parkinson’s disease. The 
authors set the stage for their discov-
ery by administering lipopolysaccharide 
(LPS) to the substantia nigra of mice 
using stereotaxic injections (a tech-
nique that uses a coordinate system 
to precisely target an injection needle 
to particular regions of the brain). This 
treatment triggers local inflammation 
and leads to a loss of neurons express-
ing tyrosine hydroxylase (TH+). They 
demonstrate that inflammation induces 
Nurr1 expression and that local knock-figure 1. A nurr1 Pathway for Transrepression of Inflammatory Gene expression
A model for Nurr1 transrepression based on the work of Saijo et al. (2009). 
(A) Inflammatory signals promote the expression of inflammatory genes through activation of NF-κB 
signaling and the recruitment of coactivator complexes, such as p300/CBP, by the NF-κB subunit p65 
to inflammatory promoters. 
(B) In cells expressing Nurr1, such as microglia, inflammatory signals also trigger Nurr1 phosphorylation 
(by Nemo-like kinase; NLK) and sumoylation. This promotes its interaction with p65 leading to the recruit-
ment of the CoREST complex to the promoters of inflammatory genes.Cein key phosphorylation sites, coupled 
with the use of kinase inhibitors, identify 
GSK3β-mediated phosphorylation of p65 
as a signal for recruitment of Nurr1 to p65. 
Phosphorylation of serine 468 drives the 
interaction of Nurr1 and p65, resulting in 
the attenuation of inflammatory gene tran-
scription by NF-κB. Analogous to PPAR- 
and LXR-mediated transrepression, Nurr1 
repression of inflammatory promoters also 
requires sumoylation of Nurr1 at key lysine 
residues (Ghisletti et al., 2007; Pascual 
et al., 2005). Treatment of cells with the 
inflammatory cytokine interleukin 1β (IL-1β) 
promotes Nurr1 sumoylation.
Another important piece in this puz-
zle is the CoREST repressor complex, 
which the authors identify as an essen-
tial player in Nurr1-mediated transre-
pression. Previous work has shown that 
CoREST represses the expression of 
neural-specific genes in non-neural cells 
via binding to specific silencing elements 
(Ballas et al., 2005). CoREST recruits an 
array of proteins to target promoters in 
order to effect repression. These include 
histone deacetylases (HDACs), the his-
tone methyltransferase G9a, histone 
demethylase, and lysine-specific dem-
ethylase 1 (LSD1). The authors show that 
Nurr1 interacts directly with CoREST and 
find that recruitment of G9a, LSD1, and 
HDAC1 is required for Nurr1/CoREST-down of Nurr1 (by injection of lentiviral 
vectors expressing short-hairpin RNAs) 
enhances the loss of TH+ neurons. 
Interestingly, the primary targets for the 
neuroprotective effects of Nurr1 appear 
to be the neighboring microglia and 
astrocytic cells rather than the neurons 
themselves. In vitro studies with micro-
glia and astrocytes implicate these sup-
port cells in the release of neurotoxic 
factors that induce neuronal death.
Building on their previous studies of 
the anti-inflammatory action of PPAR and 
LXR, the authors investigated the mecha-
nisms underlying the protective effects of 
Nurr1. Examination of isolated microglia 
and astrocytes demonstrates that Nurr1 
is a potent repressor of inflammatory 
gene expression in these cells. Chroma-
tin immunoprecipitation (ChIP) analysis 
indicates that Nurr1 is recruited to the pro-
moters of LPS-responsive genes. Interest-
ingly, the ability of Nurr1 to inhibit these 
promoters is signal specific but does not 
require direct binding to a specific DNA 
sequence. Thus, Nurr1 appears to act 
as a transrepressor, similar to the ligand-
dependent nuclear receptors PPAR and 
LXR. The authors provide evidence from 
coimmunoprecipitation experiments that 
Nurr1-mediated transrepression involves 
the physical association of Nurr1 with the 
p65 subunit of NF-κB (Figure 1). Mutations ll 137, April 3, 2009 ©2009 Elsevier Inc. 27
dependent repression. The authors also 
report that the Nurr1-CoREST interac-
tion is stimulated by phosphorylation of 
Nurr1 by Nemo-like kinase. Lastly, ChIP 
analysis of iNOS promoter occupancy 
following stimulation by LPS suggests 
a temporal model of transrepression in 
which p65 binding precedes Nurr1 asso-
ciation, which is followed by recruitment 
of  CoREST to the complex.
The Saijo et al. study provides impor-
tant insights into the ability of Nurr1 and 
 CoREST to modulate neuroinflammation. 
The work unravels molecular mechanisms 
that may underlie human neurological dis-
ease and opens the door for future work on 
inflammatory signaling in the brain. These 
studies also provide a better understand-
ing of how transrepression is achieved at 
the molecular level. Interestingly, certain 
components of the transrepression mech-
anism appear to be conserved between 
different nuclear receptors, such as the 
requirement for sumoylation and the inter-
action with NF-κB proteins and corepres-
sors. At the same time, Saijo et al. illustrate 
how different nuclear receptors utilize dis-
tinct corepressor complexes to repress 
gene expression in a signal- and context-
dependent manner.28 Cell 137, April 3, 2009 ©2009 Elsevier Inc
Cancer progression from the primary 
phase to the metastatic phase rep-
resents one of the key determinants 
of prognosis and outcome for cancer 
patients. However, the mechanistic 
details behind the metastatic spread of 
cancer remain obscure. Although the 
β-tting on p63 a
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Although much is known about th
have been found. Adorno et al. (2
uncover an intricate mechanism
transforming growth factor β.Finally, the work prompts a number of 
interesting questions to be addressed 
in future studies. For example, the three 
NR4A receptors (Nurr77, Nurr1, and 
Nor1) regulate overlapping target genes 
in some cell types. Do Nurr77 and Nor1 
also interact with CoREST in response to 
inflammatory signals? What is the rela-
tive contribution of transrepression and 
direct gene activation in NR4A-depen-
dent regulation of inflammation? Sumoy-
lation appears to be a critical component 
of the transrepression mechanism. In the 
PPAR and LXR transrepression path-
ways, sumoylation of the receptor is trig-
gered by ligand binding. Is Nurr1 sumoy-
lation responsive to other cellular signals 
in addition to IL-1β? Is the Nurr1/CoREST 
transrepression pathway intact in mono-
cytes and macrophages, and if so, does 
this repression pathway also have a role 
in peripheral inflammation? Lastly, there 
is strong evidence that neuroinflamma-
tion contributes to the pathogenesis of a 
number of diseases, including Alzheim-
er’s disease and multiple sclerosis. It will 
be important to determine if this repres-
sion pathway is altered in these diseases 
and whether NR4A receptors might rep-
resent potential therapeutic targets..
cytokine transforming growth factor β 
(TGFβ) has emerged as a major player in 
the metastatic process, it has seemingly 
contradictory functions. Ordinarily a 
tumor suppressor that mediates growth 
arrest and apoptosis, TGFβ appears to 
take on the opposite role in end-stage 
s a Metastatic s
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ess Cancer Center and Department of Medicin
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009) now identify p63 as a poten
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276, 248–250.tumors where it promotes metastasis 
(Padua and Massague, 2009). Reporting 
in this issue of Cell, Adorno et al. (2009) 
identify a mechanism in cells express-
ing mutant p53, which enables TGFβ to 
switch to an oncogenic role by promot-
ing mutant p53-mediated suppression of 
uppressor
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